First AD

Second AD

Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL 

What is the potential role of triplet therapy (VEN + BTKI + OBI) in the 1L treatment of CLL? In which patients may this strategy be most appropriate?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Video Series

EHA 2024: Updates in the Treatment of CLL   

Peer Exchange

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach. 

Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024   

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL 

Frontline BTKi Selection 

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib 

Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy 

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches 

Navigating Treatment Approaches for R/R CLL 

How Experts View MAIC Data That was Presented at EHA 2024   

BTKi Intolerance in Real-world Practice & Management Strategy 

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities   

Approach to Hypertension Management With BTKi Treatment 

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib  

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing  

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL 

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673   

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL 

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies 

Clinical Pearls and Impacts to Practice from EHA 2024   